RBC Capital analyst Brian Abrahams upgraded Neurocrine (NBIX) to Outperform from Sector Perform with a price target of $137, down from $138.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target lowered to $155 from $163 at Guggenheim
- Neurocrine Biosciences Appoints Dr. Keswani as CMO
- Neurocrine names Dr. Sanjay Keswani as Chief Medical Officer
- Neurocrine price target lowered to $137 from $154 at UBS
- Neurocrine’s Strong Market Position and Growth Potential Justify Buy Rating Amid Challenges